BRPI0812034A2 - Combinações de neramexano para o tratamento de distúrbios neurodegenerativos - Google Patents

Combinações de neramexano para o tratamento de distúrbios neurodegenerativos

Info

Publication number
BRPI0812034A2
BRPI0812034A2 BRPI0812034-0A2A BRPI0812034A BRPI0812034A2 BR PI0812034 A2 BRPI0812034 A2 BR PI0812034A2 BR PI0812034 A BRPI0812034 A BR PI0812034A BR PI0812034 A2 BRPI0812034 A2 BR PI0812034A2
Authority
BR
Brazil
Prior art keywords
neramexan
combinations
treatment
neurodegenerative disorders
neurodegenerative
Prior art date
Application number
BRPI0812034-0A2A
Other languages
English (en)
Inventor
Angelika Hanschmann
Michael Althaus
Alexander Gebauer
Christopher Graham Raphael Parsons
Wojciech Danysz
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of BRPI0812034A2 publication Critical patent/BRPI0812034A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
BRPI0812034-0A2A 2007-07-27 2008-07-25 Combinações de neramexano para o tratamento de distúrbios neurodegenerativos BRPI0812034A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96225907P 2007-07-27 2007-07-27
EP07252976A EP2018854A1 (en) 2007-07-27 2007-07-27 Novel combinations of neramexane for the treatment of neurodegenerative disorders
PCT/EP2008/006162 WO2009015844A1 (en) 2007-07-27 2008-07-25 Novel combinations of neramexane for the treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
BRPI0812034A2 true BRPI0812034A2 (pt) 2014-11-18

Family

ID=38599021

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0812034-0A2A BRPI0812034A2 (pt) 2007-07-27 2008-07-25 Combinações de neramexano para o tratamento de distúrbios neurodegenerativos

Country Status (12)

Country Link
US (1) US20100190751A1 (pt)
EP (2) EP2018854A1 (pt)
JP (1) JP2010534628A (pt)
KR (1) KR20100038120A (pt)
CN (1) CN101677972A (pt)
AU (1) AU2008281016B2 (pt)
BR (1) BRPI0812034A2 (pt)
CA (1) CA2683807A1 (pt)
MX (1) MX2009012762A (pt)
RU (1) RU2432161C1 (pt)
WO (1) WO2009015844A1 (pt)
ZA (1) ZA200907827B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102106999B (zh) * 2011-02-11 2016-05-11 冯学功 一种治疗中风病后吞咽困难的中药复方制剂及其制备方法
CN103747778B (zh) 2011-06-09 2016-06-08 宝洁公司 制备包含单烷基胺双表面活性剂体系和可溶性盐的个人护理组合物的方法
JP6145946B2 (ja) * 2011-07-13 2017-06-14 サイトキネティックス， インコーポレイテッド 併用ａｌｓ療法
WO2013192610A2 (en) * 2012-06-23 2013-12-27 Fox Chase Chemical Diversity Center, Inc. Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis
RU2538613C2 (ru) * 2012-10-11 2015-01-10 Федеральное государственное бюджетное учреждение науки Институт теоретической и экспериментальной биофизики Российской академии наук Интерлейкин-10, его применение и композиция на его основе для лечения нейродегенеративных процессов в мозге
AU2020370758A1 (en) * 2019-10-25 2022-06-02 Kyoto University Preventative or therapeutic agent for tauopathy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133299A (en) * 1993-02-25 2000-10-17 Warner-Lambert Company Methods for treating neurodegenerative diseases and disorders using N-(2,6-disubstituted aromatic)-N'-pyridinyl ureas and other anticonvulsant compounds
CA2292558C (en) * 1997-06-30 2006-09-19 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane nmda receptor antagonists
JP2006502188A (ja) * 2002-09-17 2006-01-19 ニューヨーク ユニバーシティ 年齢関連記憶欠陥（ａａｍｉ）、中程度認識欠陥（ｍｃｉ）、および痴呆を細胞周期インヒビターで処置する方法
PT2982372T (pt) * 2005-04-05 2020-10-09 Univ Yale Agentes moduladores do glutamato no tratamento de distúrbios mentais
CN101247853B (zh) * 2005-04-13 2014-11-12 轴突公司 具有nos抑制活性的取代的吲哚化合物

Also Published As

Publication number Publication date
WO2009015844A1 (en) 2009-02-05
RU2432161C1 (ru) 2011-10-27
EP2180888A1 (en) 2010-05-05
CN101677972A (zh) 2010-03-24
ZA200907827B (en) 2010-07-28
RU2010107177A (ru) 2011-09-10
US20100190751A1 (en) 2010-07-29
EP2018854A1 (en) 2009-01-28
AU2008281016B2 (en) 2011-08-25
CA2683807A1 (en) 2009-02-05
KR20100038120A (ko) 2010-04-12
JP2010534628A (ja) 2010-11-11
MX2009012762A (es) 2009-12-15
AU2008281016A1 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
BRPI0918527A2 (pt) compostos para o tratamento de disturbios do cns
BRPI1010868A2 (pt) terapia gênica para distúrbios neurodegenerativos
BRPI0810082A2 (pt) 3-imidazolil-indóis para o tratamento de doenças proliferativas
BRPI0919920A2 (pt) compostos para tratamento de doenças e desordens oftálmicas
BRPI0821660A2 (pt) Combinações de agentes terapêuticos para tratamento de câncer
BRPI0807987A2 (pt) Terapia de combinação para tratamento de distúrbios imunes.
BRPI0814624A2 (pt) Tratamento de doença neurodegenerativa progresiva com ibudilaste
BRPI0819241A2 (pt) Compostos derivados de amina para o tratamento de distúrbios e doenças oftálmicas
BRPI1015569A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias.
BRPI0906746A2 (pt) Aparelho para tratamento de doença de refluxo gastresofágico
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
BR112012011730A2 (pt) tratamentos para distúrbios gastrointestinais
DK2440230T3 (da) Behandlingsregimener til behandling af neurologisk sygdom
BRPI0813670A2 (pt) Compostos para tratamento
BR112012000502A2 (pt) terapia de combinação para o tratamento de diabetes
BRPI1013618A2 (pt) pirimidinas substituídas para o tratamento de câncer
BRPI0909221A2 (pt) Desordens neurodegenerativas
BRPI0813516A2 (pt) Tratamento de distúrbios proliferativos de células b
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus
BR112012004836A2 (pt) pirazinilpiridinas úteis para o tratamento de doenças proliferativas
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
BRPI0922884A2 (pt) compostos para tratamento de câncer
BRPI1013901A2 (pt) formulação de clavulanato para neuroproteção e tratamento de distúrbios neurodegenerativos
BRPI0922367A2 (pt) enzastaurin para o tratamento de câncer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.